|
Jan 19
|
Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally
|
|
Jan 19
|
Jim Cramer on Johnson & Johnson (JNJ): ‘Things Are Not Working Their Way’
|
|
Jan 19
|
Trump's inauguration looms as earnings season rolls on: What to know this week
|
|
Jan 19
|
Is Johnson & Johnson (JNJ) the Best Cheap Stock to Buy for 2025?
|
|
Jan 18
|
Count on Dividend King Pepsi (PEP) for Stability in a Volatile Market
|
|
Jan 18
|
Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year
|
|
Jan 18
|
Why Is Cliff Asness Bullish On Johnson & Johnson (JNJ)?
|
|
Jan 18
|
3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond
|
|
Jan 17
|
Netflix's Strategic Shift Faces Test As Streaming Giant, Dow Stocks Head Into Earnings
|
|
Jan 17
|
Stocks to watch next week: Netflix, United Airlines, Burberry, EasyJet and JD Wetherspoon
|
|
Jan 17
|
Mega M&A at JP Morgan Conference 2025 — is biopharma M&A poised for a rebound?
|
|
Jan 17
|
Should Weakness in Johnson & Johnson's (NYSE:JNJ) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
|
|
Jan 16
|
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
|
|
Jan 16
|
Insights Into Johnson & Johnson (JNJ) Q4: Wall Street Projections for Key Metrics
|
|
Jan 16
|
RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer
|
|
Jan 16
|
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
|
|
Jan 16
|
By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years
|
|
Jan 15
|
J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns
|
|
Jan 15
|
J&J’s Top Rating at Risk Because of Intra-Cellular Deal
|
|
Jan 15
|
New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer
|